ABSTRACT
Introduction Predict Prostate is a freely-available online personalised risk communication tool for men newly diagnosed with non-metastatic prostate cancer. Its accuracy has been assessed in multiple validation studies but the clinical impact of the tool on patient decision-making had not previously been evaluated.
Methods A multi-centre randomised controlled trial was performed across 8 UK centres, wherein newly diagnosed men considering either active surveillance or radical treatment, were randomised to either standard of care (SOC) information or SOC and presentation of Predict Prostate. Validated questionnaires were completed assessing impact of the tool on decisional conflict, uncertainty, anxiety and understanding of survival.
Results 156 patients were included; mean age 67 years (range 44-80) and PSA of 6.9ng/ml (range 0.5-59.8). 81 were randomised to the Predict Prostate arm, and 75 to SOC information only. Mean decisional conflict scores were 26% lower in the Predict Prostate group (mean = 15.9) than in the SOC group (mean = 21.5) (p=0.01). Scores on the ‘effective decision’, ‘uncertainty’ and ‘value clarity’ subscales all indicated that the Predict Prostate group felt more informed and clear about their decision (all p<0.05). There was no significant difference in anxiety between the two groups.
Patient perceptions of 15-year prostate cancer specific mortality (PCSM) and overall survival benefit from radical treatment were considerably lower among men in the Predict Prostate group (p<0.0001). 58% of men reported the Predict Prostate estimates for PCSM were lower than expected, and 35% reported being less likely to select radical treatment. Over 90% of patients in the Predict Prostate group found it useful and 94% would recommend it to others.
Conclusion Predict Prostate reduces decisional conflict and uncertainty in non-metastatic prostate cancer and shifts patient perceptions around prognosis to be more realistic. This is the first randomised study of such a tool in this context; it demonstrates Predict Prostate can directly inform the complex decision-making process in prostate cancer.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN 28468474
Clinical Protocols
http://www.isrctn.com/ISRCTN28468474
Funding Statement
DT was supported in this work by a research scholarship from The Urology Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
East of England - Cambridge South Research Ethics Committee. Reviewed in meeting on 23 August 2018. Favourable opinion given. REC 18/EE/0254. IRAS ID 249699 Health Research Authority full approval given 10 October 2018
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Formal requests for access to data should be made to the authors.
